Hoth Therapeutics filed two US provisional patent applications, including a patent covering the topical treatment of radiation-induced skin toxicity in oncology patients.
The second provisional patent application addresses dermatologic toxicities associated with emerging targeted cancer therapies, including second and third menin inhibitors.
Together, these dual filings aim to secure priority intellectual property rights around the use of HT-001 to treat dermatologic toxicities across multiple oncology treatment modalities, including radiation therapy and next-generation targeted agents.
Hoth’s patent filings seek to protect the use of HT-001 to target neurogenic and inflammatory pathways implicated in therapy-induced skin injury. HT-001 is a once-daily topical gel formulated with a US Food and Drug Administration (FDA)-approved neurokinin-1 receptor antagonist (NK1RA). This mechanism mitigates inflammatory pathways triggered by EGFR inhibition, particularly Substance P-driven responses that lead to skin breakdown. By targeting the neuroinflammatory axis, HT-001 reduces symptoms without immunosuppression or systemic toxicity.
“These filings represent a meaningful expansion of our intellectual property estate into an increasingly important area of oncology care,” says Robb Knie of Hoth Therapeutics, in a news release. “As cancer therapies advance, the ability to manage treatment-related toxicities is becoming essential. We believe this emerging platform highlights our strategy of identifying differentiated, mechanism-driven opportunities that can address significant unmet needs while creating long-term shareholder value.”